EXHIBIT B

6. (Amended) A method for [preventing or] treating an [antibody-mediated] IgE-mediated disease in a patient, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of [a] an anti-CD40 monoclonal antibody or an antigen binding fragment thereof, said monoclonal antibody or fragment thereof being free of significant agonistic activity and binding [capable of binding] to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen on the surface of said B cell prevents the growth or differentiation of the B cell[, in a pharmaceutically acceptable carrier].